Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Lack of progress by week 8 usually indicates your dose is subtherapeutic, diet changes are insufficient, or your genetic profile responds better to a different GLP-1 or dual compound
Weight regain is common after semaglutide is stopped
Continue reading to learn more about GLP-1 drugs and their potential benefits and risks for people currently living with breast cancer and for breast cancer survivors
Timeline Estimates: Based on typical pharmaceutical development, if Eli Lilly started Phase 1 trials for oral tirzepatide today, FDA approval would likely be 5-7 years away at minimum
Coverage depends on your insurance provider, diagnosis, and state regulations
Plans widely cover GLP-1 receptor agonists for type 2 diabetes
US$ 20.32
US$ 24.57
US$ 28.84
US$ 26.05
US$ 23.47
US$ 27.93
US$ 20.05
US$ 21.71
